U.S. Airlines Stock News

NasdaqCM:DFDV
NasdaqCM:DFDVConsumer Finance

DeFi Development (DFDV) Swings To US$144.5 Million Quarterly Loss Challenging Bullish Narratives

DeFi Development (DFDV) just wrapped up FY 2025 with Q4 total revenue of US$4.5 million and a basic EPS loss of US$5.48, while trailing twelve month revenue sat at US$11.4 million against a basic EPS loss of US$4.00. Over the past six reported quarters, the company has seen quarterly revenue move from US$0.62 million in Q4 2024 to US$4.5 million in Q4 2025, with EPS swinging between a loss of US$0.05 and a profit of US$2.41 before landing back in loss-making territory. This leaves investors...
NasdaqGS:DCOM
NasdaqGS:DCOMBanks

A Look At Dime Community Bancshares (DCOM) Valuation As Analyst Coverage And Dividend Support Investor Interest

Dime Community Bancshares (DCOM) is back on dividend watch, with the bank’s board declaring a quarterly cash payout of $0.25 per share and highlighting an uninterrupted dividend record that income focused investors often track closely. See our latest analysis for Dime Community Bancshares. The reaffirmed dividend comes as Dime Community Bancshares’ share price sits at $33.82, with a 90 day share price return of 12.4% and a 1 year total shareholder return of 22.4%, suggesting momentum has been...
NasdaqCM:SEZL
NasdaqCM:SEZLDiversified Financial

Is Sezzle’s (SEZL) Switch to PwC Quietly Reframing Its Governance and Risk Narrative?

On March 16, 2026, Sezzle Inc. dismissed Baker Tilly US, LLP as its independent registered public accounting firm and, with Audit Committee approval, engaged PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026, subject to PwC’s standard client acceptance procedures. This shift to a Big Four auditor marks a meaningful change in Sezzle’s external oversight, which many investors closely monitor when assessing governance and financial reporting quality. Next, we’ll examine...
NYSE:NIQ
NYSE:NIQMedia

NIQ Packaging Analytics Launch And Data Tie Up Test Undervaluation Narrative

NIQ Global Intelligence (NYSE:NIQ) has launched its Packaging Strategic Planner Global platform, described as the first harmonized solution for tracking packaging performance worldwide. The platform offers monthly insights into packaging effectiveness across categories, materials, and markets, supported by the new EQ2 metric for improved data accuracy. NIQ and MRI-Simmons have joined Comscore’s Data Partner Network to combine consumer and retail insights with privacy-first audience targeting...
NYSE:LEN
NYSE:LENConsumer Durables

Lennar (LEN) Valuation Check As Macro Tailwinds And New Florida Townhomes Support Investor Confidence

Lennar (LEN) is back in focus after two catalysts: easing geopolitical tensions that supported homebuilder sentiment and the company’s launch of three new townhome communities in Southwest Florida. See our latest analysis for Lennar. Even with the latest 2.31% 1 day share price gain to US$86.84 and fresh headlines around its Florida townhome launches, Lennar’s 30 day share price return of 24.06% and 1 year total shareholder return of 22.81% point to momentum that has faded over time as...
NasdaqGS:SHOO
NasdaqGS:SHOOLuxury

A Look At Steven Madden (SHOO) Valuation After Mixed Recent Share Price Returns

Steven Madden (SHOO) has drawn investor attention after recent trading left the shares with a one-month return of a 6.0% decline and a three-month move of an 18.5% decline, despite a one-year total return of 26.96%. See our latest analysis for Steven Madden. The recent 1-day share price return of 4.08% and 7-day share price return of 1.34% sit against weaker 30 and 90 day share price returns, suggesting short term momentum is stabilising after a softer patch. The 1 year total shareholder...
NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

A Look At Viking Therapeutics (VKTX) Valuation As VANQUISH 2 Enrollment Milestone Advances VK2735 Program

Viking Therapeutics (VKTX) has completed patient enrollment in its Phase 3 VANQUISH-2 trial of VK2735, a dual GLP-1/GIP agonist for obesity and type 2 diabetes, drawing attention to upcoming efficacy and safety readouts. See our latest analysis for Viking Therapeutics. The latest VANQUISH-2 enrollment milestone comes after a volatile stretch in the share price. The stock recorded an 8.76% 1-day share price return, alongside a 30-day share price return reflecting a 3.84% decline and a...
NasdaqGS:JBLU
NasdaqGS:JBLUAirlines

JetBlue Bag Fee Hike Links Iran Fuel Pressures To Investor Concerns

JetBlue Airways has raised checked baggage fees, citing higher jet fuel costs linked to the ongoing Iran conflict. The fee change is intended to help offset increased operating expenses that are affecting day to day flight operations. This development has direct implications for passengers and could influence how other airlines think about pricing. For investors watching JetBlue Airways, ticker NasdaqGS:JBLU, the move comes as the share price sits at $4.42. The stock has fallen 20.2% over...
NasdaqGS:TLRY
NasdaqGS:TLRYPharmaceuticals

Tilray Brands (TLRY) Valuation Check As New Beverage Launches And Q3 Earnings Date Draw Focus

Tilray Brands (TLRY) is back in focus after fresh product launches in its beverage portfolio and the approach of its Q3 2026 earnings release and earnings call scheduled for April 1. See our latest analysis for Tilray Brands. Despite the fresh Popsicle Hard and Shock Top High Voltage launches and attention around the upcoming Q3 update, Tilray Brands’ recent share price returns point to fading momentum, with a 30 day share price return of a 17.79% decline and a 3 year total shareholder return...
NYSE:AA
NYSE:AAMetals and Mining

Assessing Alcoa (AA) Valuation After Middle East Supply Disruptions And Aluminum Price Strength

Missile strikes on major Middle Eastern aluminum producers have pushed supply risk to the forefront, and Alcoa (AA) is suddenly back in focus as investors reassess global pricing power and potential margins. See our latest analysis for Alcoa. The recent jump in aluminum prices and supply concerns has fed directly into Alcoa’s share price momentum, with a 17.03% 7 day share price return, 24.82% 90 day share price return and a 1 year total shareholder return of 122.54%, suggesting that optimism...
NYSE:LH
NYSE:LHHealthcare

Should Labcorp’s Expanded Illumina Oncology Partnership Reshape the Precision Medicine Story for LH Investors?

In March 2026, Illumina and Labcorp expanded their precision oncology collaboration to develop and distribute next-generation sequencing-based cancer tests, including co-commercializing Labcorp's FDA-authorized PGDx elio plasma focus Dx liquid biopsy alongside Illumina's FDA-approved TruSight Oncology Comprehensive for solid tumors. This alliance aims to widen access to both tissue and liquid biopsy biomarker testing, support companion diagnostic development for drugmakers, and strengthen...
NYSE:BANC
NYSE:BANCBanks

A Look At Banc Of California’s (BANC) Valuation As Debt Redemption And Buybacks Take Center Stage

Redemption and Buyback Moves Put Capital Management in Focus Banc of California (BANC) drew investor attention after announcing plans to redeem $385 million of subordinated notes originally issued by Pacific Western Bank and to extend its share repurchase plan through March 16, 2027. See our latest analysis for Banc of California. The latest debt redemption and buyback announcements arrive after a 1-day share price return of 3.53% to US$17.58. However, the 90-day share price return of 8.86%...
NYSE:INSP
NYSE:INSPMedical Equipment

Is It Time To Reassess Inspire Medical Systems (INSP) After Its Steep Multi‑Year Share Price Slump

If you are wondering whether Inspire Medical Systems at around US$51.58 is starting to look interesting, the key question is how its current price stacks up against its underlying worth. The share price has been under pressure, with a 0.9% decline over the last week, a 20.0% decline over the last month, and a 44.1% decline year to date, adding to a 67.4% decline over the past year and 77.2% and 75.1% declines over the past three and five years respectively. These returns have kept Inspire...
NYSE:FLUT
NYSE:FLUTHospitality

Can Jefferies’ FanDuel Predicts Call Subtly Recast Flutter’s (FLUT) U.S. Betting Profit Narrative?

In late March 2026, Jefferies issued positive coverage on Flutter Entertainment, highlighting the FanDuel Predicts app’s strong download momentum and potential to add an estimated US$125.00 million in annual revenue that is not yet reflected in company guidance or market forecasts, even as regulatory scrutiny of prediction markets increases. An interesting angle is how UConn’s upset win over Duke underscored the way underdog victories can support sportsbook profitability, indirectly...
NYSE:APAM
NYSE:APAMCapital Markets

Is Artisan Partners (APAM) Still Attractive After Recent Share Price Weakness?

Wondering if Artisan Partners Asset Management at around US$36.39 is offering value right now, or if the easy money has already been made. The stock is up 1.6% over the last 7 days, although it shows a 9.7% decline over 30 days, a 12.1% decline year to date, and a 0.3% return over the past year, which may have shifted how investors see its risk and return profile. Recent coverage has focused on the stock’s mixed return picture, with a modest 0.3% 1 year return sitting alongside a 46.5%...
NasdaqGS:MAT
NasdaqGS:MATLeisure

A Look At Mattel (MAT) Valuation As Masters Of The Universe Rollout And Restructuring Take Shape

Mattel (MAT) is back in focus after unveiling a global Masters of the Universe product program tied to the 2026 live action film, alongside fresh layoffs at its El Segundo headquarters. See our latest analysis for Mattel. Despite the Masters of the Universe launch and ongoing restructuring, Mattel’s 30 day share price return decline of 14.28% and year to date share price return decline of 27.5% sit alongside a 1 year total shareholder return decline of 25.22%, pointing to fading momentum...
NasdaqGS:ALAB
NasdaqGS:ALABSemiconductor

Astera Labs (ALAB) Valuation Check After FTSE Index Inclusion And New Shelf Registration

Astera Labs (ALAB) has drawn fresh attention after being added to the FTSE All-World Index and filing a new shelf registration. This filing gives the company flexibility to issue up to US$704.8 million in common stock. See our latest analysis for Astera Labs. Astera Labs’ recent FTSE All-World Index inclusion and shelf registration come after a mixed price pattern, with a 9.30% 1 day share price return contrasting with weaker 30 day and year to date share price returns, while the 1 year total...
NYSE:FIX
NYSE:FIXConstruction

Comfort Systems USA (FIX) Joins FTSE All-World Index as Analysts Scrutinize Earnings Power and Backlog

Comfort Systems USA, Inc. (NYSE: FIX) was added to the FTSE All-World Index (USD) on 21 March 2026, further cementing its position among globally tracked construction and building-services companies. This index inclusion coincides with growing attention on the company’s upcoming fiscal Q1 2026 earnings, where analysts are looking for double-digit earnings growth and continued backlog strength. We’ll now examine how the FTSE All-World Index inclusion could influence Comfort Systems USA’s...
NYSE:ANF
NYSE:ANFSpecialty Retail

A Look At Abercrombie & Fitch’s (ANF) Valuation After Earnings Growth And Buybacks Fuel Recent Market Move

Abercrombie & Fitch (ANF) is drawing attention after operational improvements, including average comparable store sales growth of 10% over the past two years, a reported 62.8% gross margin and very large earnings per share growth supported by share repurchases. See our latest analysis for Abercrombie & Fitch. The recent 1-day share price return of 4.79% takes Abercrombie & Fitch to US$91.37. However, this sits against a 90-day share price return of negative 27.41% and a 1-year total...
NYSE:HIMS
NYSE:HIMSHealthcare

Did Hims & Hers' Novo Nordisk GLP-1 Partnership Just Shift Hims & Hers Health's (HIMS) Investment Narrative?

In March 2026, Hims & Hers Health announced a collaboration with Novo Nordisk to offer eligible customers a broad range of FDA-approved GLP-1 medications, including the Wegovy pill, alongside a new weight loss membership featuring 24/7 provider access and personalized support starting at US$39 for the first month and US$149 thereafter. This partnership expands Hims & Hers’ presence in the fast-growing medical weight management category by pairing branded GLP-1 therapies with a...
NYSE:MCO
NYSE:MCOCapital Markets

Is It Time To Reassess Moody's (MCO) After Recent Share Price Weakness?

This article walks through key numbers to help you judge whether Moody's current share price lines up with its underlying worth and if the stock looks expensive, cheap or somewhere in between. Moody's last closed at US$436.25, with returns of 1.8% over 7 days, an 8.7% decline over 30 days, a 12.6% decline year to date and a 6.2% decline over the last year. The 3 year and 5 year returns stand at 47.1% and 47.0% respectively. Recent coverage has focused on how Moody's performance over 3 and 5...
NasdaqGS:INTC
NasdaqGS:INTCSemiconductor

Intel (INTC) Valuation Check After Recent Share Price Momentum And Foundry Transition

Intel stock in focus Intel (INTC) is back in focus for investors after recent share price moves and fresh attention on its foundry and data center businesses, prompting a closer look at its current fundamentals and valuation. See our latest analysis for Intel. At a share price of US$44.13, Intel has seen a sharp 7.1% 1 day share price return, a 19.6% 90 day share price return, and a very large 1 year total shareholder return. This suggests momentum has recently strengthened after a softer 1...
NYSE:BRK.A
NYSE:BRK.ADiversified Financial

Berkshire Adds OxyChem As New Earnings Engine In Chemicals Expansion

Berkshire Hathaway has completed the acquisition of Occidental Petroleum's OxyChem subsidiary. The deal expands Berkshire's chemicals presence and supports Occidental's efforts to reduce debt and focus on energy operations. The transaction adds a new earnings stream within Berkshire's diversified portfolio under ticker NYSE:BRK.A. Berkshire Hathaway, trading under NYSE:BRK.A, is adding OxyChem to a portfolio that already spans insurance, energy, transportation and consumer businesses. The...
NasdaqGM:MDB
NasdaqGM:MDBIT

How MongoDB’s New CRO Hire to Lead Global Sales At MongoDB (MDB) Has Changed Its Investment Story

MongoDB, Inc. recently announced that outgoing Chief Revenue Officer Paul Capombassis will support a leadership transition through the second quarter of 2026, as Ryan Mac Ban, formerly CRO at Confluent, steps into the Chief Revenue Officer role effective April 27, 2026 to lead the global sales organization. This hire brings two decades of enterprise software sales experience into MongoDB’s go-to-market leadership at a time when the company is emphasizing its next phase of growth and...